Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Infections, Streptococcal
Interventions: Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,806 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more

Conditions: Premenstrual Dysphoric Disorder
Interventions: PH80, Placebo intranasal spray; Drug
Lead sponsor: Pherin Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions: LY3540378, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Tucson, Arizona • Covina, California • Northridge, California + 18 more

Conditions: Diabetic Neuropathy, Painful, Diabetic Neuralgia, Diabetic Polyneuropathy, Diabetic Mononeuropathy
Interventions: infrared light, infrared light; placebo; Device
Lead sponsor: East Bay Institute for Research and Education; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Martinez, California

Conditions: Liver Disease
Interventions: Minocycline (yes/no), Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 56
States / cities: Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more

Conditions: Venous Thrombosis, Pulmonary Embolism
Interventions: Apixaban, Enoxaparin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years and older
Enrollment: 6,758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more

Conditions: Anthocyanins
Interventions: ACRB, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Ulcerative Colitis
Interventions: Placebo, Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,064 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 52
States / cities: Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more

Conditions: Healthy
Interventions: LY3410738, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Conditions: Menopause, Perimenopause
Interventions: Hemp-derived cannabinoids, Placebo; Drug
Lead sponsor: Washington State University; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Pullman, Washington

Conditions: Peripheral Artery Disease, Peripheral Vascular Diseases, Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
Interventions: Vumerity, Placebo; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Rheumatoid Arthritis
Interventions: ADL5859, Naproxen, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more

Conditions: Zika Virus
Interventions: ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Moderate to Severe Psoriatic Arthritis
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Huntington Beach, California • Duncansville, Pennsylvania • Philadelphia, Pennsylvania + 5 more

Conditions: Episodic Cluster Headache
Interventions: Civamide (Zucapsaicin); Drug
Lead sponsor: Winston Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 23 more

Conditions: Anxiety Disorders
Interventions: lorazepam, placebo, paroxetine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Glendale, California • Northridge, California • Orange, California + 10 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 17
States / cities: Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more

Conditions: Chronic Low Back Pain
Interventions: Lidoderm®; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 6
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 3 more

Conditions: Myeloma
Interventions: Minocycline, Placebo, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bleeding, Implants, Breakthrough Bleeding
Interventions: Placebo, Curcumin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Treatment of Painful Diabetic Neuropathy With Photon Stimulation

Minocycline Administration During Human Liver Transplantation

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Study of LY3410738 in Healthy Adult Participants

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users